Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters










Publication year range
1.
Cell Death Dis ; 6: e1848, 2015 Aug 06.
Article in English | MEDLINE | ID: mdl-26247733

ABSTRACT

Protein tyrosine kinase 6 (PTK6) expression, activation, and amplification of the PTK6 gene have been reported in ERBB2/HER2-positive mammary gland cancers. To explore contributions of PTK6 to mammary gland tumorigenesis promoted by activated ERBB2, we crossed Ptk6-/- mice with the mouse mammary tumor virus-ERBB2 transgenic mouse line expressing activated ERBB2 and characterized tumor development and progression. ERBB2-induced tumorigenesis was significantly delayed and diminished in mice lacking PTK6. PTK6 expression was induced in the mammary glands of ERBB2 transgenic mice before tumor development and correlated with activation of signal transducer and activator of transcription 3 (STAT3) and increased proliferation. Disruption of PTK6 impaired STAT3 activation and proliferation. Phosphorylation of the PTK6 substrates focal adhesion kinase (FAK) and breast cancer anti-estrogen resistance 1 (BCAR1; p130CAS) was decreased in Ptk6-/- mammary gland tumors. Reduced numbers of metastases were detected in the lungs of Ptk6-/- mice expressing activated ERBB2, compared with wild-type ERBB2 transgenic mice. PTK6 activation was detected at the edges of ERBB2-positive tumors. These data support roles for PTK6 in both ERBB2-induced mammary gland tumor initiation and metastasis, and identify STAT3, FAK, and BCAR1 as physiologically relevant PTK6 substrates in breast cancer. Including PTK6 inhibitors as part of a treatment regimen could have distinct benefits in ERBB2/HER2-positive breast cancers.


Subject(s)
Gene Expression Regulation, Neoplastic , Lung Neoplasms/genetics , Mammary Neoplasms, Experimental/genetics , Protein-Tyrosine Kinases/genetics , Receptor, ErbB-2/genetics , Retroviridae Infections/genetics , Tumor Virus Infections/genetics , Animals , Carcinogenesis , Cell Proliferation , Crk-Associated Substrate Protein/genetics , Crk-Associated Substrate Protein/metabolism , Crosses, Genetic , Disease Progression , Female , Focal Adhesion Kinase 1/genetics , Focal Adhesion Kinase 1/metabolism , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Mammary Glands, Animal/metabolism , Mammary Glands, Animal/pathology , Mammary Glands, Animal/virology , Mammary Neoplasms, Experimental/metabolism , Mammary Neoplasms, Experimental/pathology , Mammary Tumor Virus, Mouse/pathogenicity , Mammary Tumor Virus, Mouse/physiology , Mice , Mice, Knockout , Phosphorylation , Protein-Tyrosine Kinases/deficiency , Receptor, ErbB-2/metabolism , Retroviridae Infections/metabolism , Retroviridae Infections/pathology , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , Signal Transduction , Tumor Virus Infections/metabolism , Tumor Virus Infections/pathology
2.
Oncogenesis ; 2: e81, 2013 Dec 09.
Article in English | MEDLINE | ID: mdl-24323291

ABSTRACT

Protein tyrosine kinase 6 (PTK6, also called BRK) is an intracellular tyrosine kinase expressed in the majority of human breast tumors and breast cancer cell lines, but its expression has not been reported in normal mammary gland. To study functions of PTK6 in vivo, we generated and characterized several transgenic mouse lines with expression of human PTK6 under control of the mouse mammary tumor virus (MMTV) long terminal repeat. Ectopic active PTK6 was detected in luminal epithelial cells of mature transgenic mammary glands. Lines expressing the MMTV-PTK6 transgene exhibited more than a two-fold increase in mammary gland tumor formation compared with nontransgenic control animals. PTK6 activates signal transducer and activator of transcription 3 (STAT3), and active STAT3 was detected in PTK6-positive mammary gland epithelial cells. Endogenous mouse PTK6 was not detected in the normal mouse mammary gland, but it was induced in mouse mammary gland tumors of different origin, including spontaneous tumors that developed in control mice, and tumors that formed in PTK6, H-Ras, ERBB2 and PyMT transgenic models. MMTV-PTK6 and MMTV-ERBB2 transgenic mice were crossed to explore crosstalk between PTK6 and ERBB2 signaling in vivo. We found no significant increase in tumor incidence, size or metastasis in ERBB2/PTK6 double transgenic mice. Although we detected increased proliferation in ERBB2/PTK6 double transgenic tumors, an increase in apoptosis was also observed. MMTV-PTK6 clearly promotes mammary gland tumorigenesis in vivo, but its impact may be underrepresented in our transgenic models because of induction of endogenous PTK6 expression.

3.
Oncogene ; 32(36): 4304-12, 2013 Sep 05.
Article in English | MEDLINE | ID: mdl-23027128

ABSTRACT

Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase expressed in epithelial cancers. Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Relocalization of PTK6 in prostate cancers contributes to increased growth. Although not expressed in normal breast or ovary, PTK6 promotes anchorage-independent survival of breast and ovarian tumor cells. We identified several potential PTK6 substrates in the human SW620 colon cancer cell line using mass spectrometry, including FAK (focal adhesion kinase). We show that FAK is a direct substrate of PTK6 in vitro and in vivo. Expression of membrane-targeted active PTK6 (Palm-PTK6-YF) induces constitutive activation of FAK and cell morphology changes, which are independent of SRC family kinases in Src-/-, Yes-/-, Fyn-/- (SYF) mouse embryonic fibroblasts (MEFs). Palm-PTK6-YF expressing SYF cells are transformed and overcome contact inhibition, form colonies in transformation assays, proliferate in suspension and form tumors in a xenograft model. Expression of FAK and Palm-PTK6-YF in Fak-/- MEFs synergistically activates AKT and protects cells against anoikis. However, expression of Palm-PTK6-YF in Akt1/2-/- MEFs fails to protect cells from anoikis, indicating AKT is critical in PTK6 and FAK-mediated survival signaling. In a conditional Pten knockout murine prostate cancer model, we identify prostate epithelial cells with enhanced activation of endogenous PTK6 and FAK at the plasma membrane. Knockdown of PTK6 in the PC3 human prostate cancer cell line disrupts FAK and AKT activation and promotes anoikis, which can be rescued by exogenous expression of FAK. Our data reveal important roles for a PTK6-FAK-AKT signaling axis in promoting anchorage-independent cell survival.


Subject(s)
Anoikis , Focal Adhesion Protein-Tyrosine Kinases/metabolism , Neoplasm Proteins/metabolism , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , src-Family Kinases/metabolism , Animals , Anoikis/genetics , Cell Line , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Enzyme Activation , Fibroblasts/metabolism , Fibroblasts/pathology , Gene Knockdown Techniques , Humans , Male , Mice , Neoplasm Proteins/genetics , Phosphorylation , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Protein-Tyrosine Kinases/genetics , Signal Transduction , Substrate Specificity , src-Family Kinases/genetics
4.
Oral Oncol ; 40(10): 1040-7, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15509496

ABSTRACT

BRK is a non-receptor tyrosine kinase whose functional role is poorly understood. Although it is an epithelial specific kinase, its expression appears to be tissue specific. To date, little is known about BRK expression in human oral epithelium. We investigated expression of BRK in human oral squamous cell carcinomas (OSCC) and normal oral epithelium (NOE) using immunohistochemistry, laser confocal microscopy and Western blotting. The subcellular localization of BRK was identified by confocal microscopy and Western blotting of nuclear and cytoplasmic extracts from these cells. The results indicate that NOE express higher levels of BRK compared with OSCC cells. In NOE and moderately differentiated OSCC cells, BRK was localized in the nucleus and cytoplasm. However, in poorly differentiated OSCC cells, BRK was localized in perinuclear regions. These results suggest that BRK expression differs in normal and OSCC which may reflect a possible functional involvement in OSCC.


Subject(s)
Carcinoma, Squamous Cell/enzymology , Mouth Neoplasms/enzymology , Protein-Tyrosine Kinases/metabolism , Blotting, Western , Humans , Microscopy, Confocal , Mouth Mucosa/enzymology , Neoplasm Proteins , Tumor Cells, Cultured
5.
Oncogene ; 20(20): 2587-99, 2001 May 03.
Article in English | MEDLINE | ID: mdl-11420669

ABSTRACT

p53 tumor suppressor is a subject of several post-translational modifications, including phosphorylation, ubiquitination and acetylation, which regulate p53 function. A new covalent modification of p53 at lysine 386 by SUMO-1 was recently identified. To elucidate the function of sumoylated p53, we compared the properties of wild type p53 and sumoylation-deficient p53 mutant, K386R. No differences were found between wild type p53 and K386R mutant of p53 in transactivation or growth suppression assays. Moreover, overexpression of SUMO-1 has no effect on p53-regulated transcription. Biochemical fractionation showed that sumoylated p53 is localized in the nucleus and is tightly bound to chromatin structures. p53 and SUMO-1 co-localized in PML nuclear bodies in 293 cells and the nucleoli in MCF7 and HT1080 cells. However, sumoylation-deficient p53 mutant showed a similar pattern of intranuclear localization, suggesting that SUMO-1 does not target p53 to subnuclear structures. These data indicate that SUMO-1 modification of p53 at lysine 386 may not be essential for p53's cellular localization, transcriptional activation, or growth regulation.


Subject(s)
Tumor Suppressor Protein p53/physiology , Ubiquitins/metabolism , Amino Acid Sequence , Cell Division/physiology , Cell Nucleus/metabolism , Chromatin/metabolism , DNA Damage , Humans , SUMO-1 Protein , Sequence Homology, Amino Acid , Transcriptional Activation , Transfection , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Ubiquitins/biosynthesis , Ubiquitins/genetics
6.
Proc Natl Acad Sci U S A ; 98(8): 4510-5, 2001 Apr 10.
Article in English | MEDLINE | ID: mdl-11274368

ABSTRACT

The cyclin-dependent kinase inhibitor p21((WAF1/CIP1)) inhibits proliferation both in vitro and in vivo, and overexpression of p21 in normal and tumor cell lines results in cell cycle arrest. In contrast, ectopic expression of Myc alleviates G(1) cell cycle arrest. Recent studies showed that Myc can repress p21 transcription, thereby overriding a p21-mediated cell cycle checkpoint. We found that activation of a Myc-estrogen receptor fusion protein by 4-hydroxytamoxifen in mouse cells resulted in suppression of endogenous p21 transcription. This effect was observed in the absence of de novo protein synthesis and was independent of histone deacetylase activity. In transient transfection studies, Myc effectively repressed p21 promoter constructs containing only 119 bp of sequence upstream of the transcription start site. This region contains multiple Sp1-binding sites and a potential initiator element, but no canonical Myc DNA-binding sites. Deletion of the potential initiator element does not affect repression of the p21 promoter by c-Myc. Coimmunoprecipitation and glutathione S-transferase pull-down experiments demonstrate that c-Myc may form complexes with Sp1/Sp3. We found that the central region of c-Myc interacts with the zinc finger domain of Sp1. Because Sp1 is required for p21 transcription, it is possible that Myc may down-regulate p21 transcription, at least in part, by sequestering Sp1. Repression of the p21 promoter may contribute to the ability of c-Myc to promote cell proliferation.


Subject(s)
Cyclins/genetics , DNA-Binding Proteins/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins c-myc/physiology , Sp1 Transcription Factor/metabolism , Transcription Factors/metabolism , Animals , Base Sequence , Cell Line, Transformed , Cyclin-Dependent Kinase Inhibitor p21 , DNA Primers , Humans , Mice , Protein Binding , Proto-Oncogene Proteins c-myc/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sp3 Transcription Factor
7.
Oncogene ; 19(45): 5182-8, 2000 Oct 26.
Article in English | MEDLINE | ID: mdl-11064455

ABSTRACT

The CDK inhibitor p21WAF1/CIP1 is a negative regulator of the cell cycle, and its expression is induced during terminal differentiation in vitro and in vivo. Expression of p21 is controlled at the transcriptional level by both p53-dependent and -independent mechanisms. Our previous studies established that p21 is expressed in the Caco-2 adenocarcinoma cell line, and its expression is induced by a p53-independent mechanism during differentiation of these cells. Here we have found that transcription of p21 in Caco-2 cells is controlled primarily by the transcription factors Sp1 and Sp3 through two Sp1 binding sites, Sp1-1 and Sp1-2, located between -119 and -114 bp and between -109 and -104 bp of the p21 promoter, respectively. Sp1 and Sp3 binding to the p21 promoter increased during Caco-2 cell differentiation, while the absolute level of Sp1 did not change and the absolute level of Sp3 increased approximately twofold. Transfection experiments in the SL2 Drosophila cell line that lacks endogenous Sp3 activity demonstrated that Sp1 transactivates the p21 promoter primarily through the Sp1-2 site, while Sp3 acts through the Sp1-1 site. In these cells Sp3 is a stronger transactivator of the p21 promoter than Sp1. Our data suggest that induction of p21 transcription during Caco-2 differentiation is modulated by Sp1/Sp3 interactions with the p21 promoter.


Subject(s)
Adenocarcinoma/genetics , Colonic Neoplasms/genetics , Cyclins/genetics , DNA-Binding Proteins/metabolism , Sp1 Transcription Factor/metabolism , Transcription Factors/metabolism , Animals , Binding Sites , Caco-2 Cells , Cyclin-Dependent Kinase Inhibitor p21 , Drosophila/cytology , Humans , Promoter Regions, Genetic , Protein Binding , Sp3 Transcription Factor , Transcription, Genetic
8.
Mol Cell Biol ; 20(16): 6114-26, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10913193

ABSTRACT

Sik (mouse Src-related intestinal kinase) and its orthologue BRK (human breast tumor kinase) are intracellular tyrosine kinases that are distantly related to the Src family and have a similar structure, but they lack the myristoylation signal. Here we demonstrate that Sik and BRK associate with the RNA binding protein Sam68 (Src associated during mitosis, 68 kDa). We found that Sik interacts with Sam68 through its SH3 and SH2 domains and that the proline-rich P3 region of Sam68 is required for Sik and BRK SH3 binding. In the transformed HT29 adenocarcinoma cell cell line, endogenous BRK and Sam68 colocalize in Sam68-SLM nuclear bodies (SNBs), while transfected Sik and Sam68 are localized diffusely in the nucleoplasm of nontransformed NMuMG mammary epithelial cells. Transfected Sik phosphorylates Sam68 in SNBs in HT29 cells and in the nucleoplasm of NMuMG cells. In functional studies, expression of Sik abolished the ability of Sam68 to bind RNA and act as a cellular Rev homologue. While Sam68 is a substrate for Src family kinases during mitosis, Sik/BRK is the first identified tyrosine kinase that can phosphorylate Sam68 and regulate its activity within the nucleus, where it resides during most of the cell cycle.


Subject(s)
Cell Nucleus/metabolism , RNA-Binding Proteins/metabolism , src-Family Kinases/metabolism , Adaptor Proteins, Signal Transducing , DNA-Binding Proteins , HeLa Cells , Humans , Phosphorylation , Protein-Tyrosine Kinases , RNA/metabolism
9.
Oncogene ; 19(7): 961-4, 2000 Feb 17.
Article in English | MEDLINE | ID: mdl-10702805

ABSTRACT

We recently reported that E2F1 could transactivate the p21 promoter via cis-acting elements between -119 to +16 bp of the p21 gene. Here we show that activated V12-H-Ras can induce the p21 promoter through the same region of the p21 promoter by a p53-independent mechanism in NIH3T3 cells. In contrast, activated Ras was not able to induce the p21 promoter in E2F1-/- fibroblasts, suggesting that E2F1 is required for induction of the p21 promoter by activated Ras. Cotransfection of increasing concentrations of dominant negative E2F1 alone, or with dominant negative DP1 into NIH3T3 cells suppressed induction of the p21 promoter by activated Ras. These data suggest that p53-independent induction of the p21 promoter by activated Ras is mediated at least in part by E2F1. Oncogene (2000) 19, 961 - 964.


Subject(s)
Carrier Proteins , Cell Cycle Proteins , Cyclins/genetics , Cyclins/physiology , DNA-Binding Proteins , Gene Expression Regulation/genetics , Transcription Factors/physiology , Transcription, Genetic/genetics , ras Proteins/physiology , 3T3 Cells , Animals , Cell Line , Cyclin-Dependent Kinase Inhibitor p21 , E2F Transcription Factors , E2F1 Transcription Factor , Mice , Retinoblastoma-Binding Protein 1 , Transcription Factor DP1 , Transcription Factors/genetics , ras Proteins/genetics
10.
Clin Cancer Res ; 5(7): 1767-77, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10430081

ABSTRACT

Clones encoding the breast tumor kinase BRK were isolated from a normal human small intestinal cDNA library that was screened with the cDNA encoding the mouse epithelial-specific tyrosine kinase Sik. Although BRK and Sik share only 80% amino acid sequence identity, Southern blot hybridizations confirmed that the two proteins are orthologues. Sik was mapped to mouse distal chromosome 2, which shows conservation of synteny with human chromosome 20q13.3, the location of the BRK gene. BRK expression was examined in the normal gastrointestinal tract, colon tumor cell lines, and primary colon tumor samples. Like Sik, BRK is expressed in normal epithelial cells of the gastrointestinal tract that are undergoing terminal differentiation. BRK expression also increased during differentiation of the Caco-2 colon adenocarcinoma cell line. Modest increases in BRK expression were detected in primary colon tumors by RNase protection, in situ hybridization, and immunohistochemical assays. The BRK tyrosine kinase appears to play a role in signal transduction in the normal gastrointestinal tract, and its overexpression may be linked to the development of a variety of epithelial tumors.


Subject(s)
Biomarkers, Tumor/biosynthesis , Colonic Neoplasms/metabolism , Digestive System/metabolism , Protein-Tyrosine Kinases/biosynthesis , src-Family Kinases/biosynthesis , Amino Acid Sequence , Animals , Caco-2 Cells , Chromosomes, Human, Pair 20 , Colonic Neoplasms/chemistry , Humans , Mice , Molecular Sequence Data , Neoplasm Proteins , Protein-Tyrosine Kinases/chemistry , Protein-Tyrosine Kinases/genetics , Sequence Homology, Amino Acid , Tumor Cells, Cultured , src-Family Kinases/chemistry , src-Family Kinases/genetics
12.
Oncogene ; 17(26): 3435-44, 1998 Dec 31.
Article in English | MEDLINE | ID: mdl-10030667

ABSTRACT

Ryk is a ubiquitously expressed tyrosine kinase-like receptor of unknown activity and associations. We examined ryk expression in adult mouse epithelial tissues and during embryonic development at the histological level. Ryk RNA is present at greatly increased levels in cells at particular stages of epithelial differentiation: the basal layer of skin and tongue epithelia, the intervillous layer and some crypt bases of the intestine and the lower matrix region of the hair follicle. Although ryk RNA is expressed at similar levels in a variety of tissues from embryonic day 10.5 to 18.5, specific induction of ryk RNA can be seen by in situ hybridization in the basal layer of skin and hair follicle at day 15.5-16.5, and protein staining localizes to the hair follicle by immunohistochemistry. At day 4.5 and 6.5, little if any ryk is present in the blastocyst, but it is transiently induced at a high level in mature decidual cells of the uterine stroma. We review a number of independent isolations of ryk, including fruit fly and nematode members of the ryk family. Because ryk is induced in epithelial cells seeking a final place in a differentiated tissue, or during remodeling of the endometrium, and a homologous gene, derailed, is known to regulate muscle and nerve target seeking in Drosophila, ryk may also be involved in cellular recognition of appropriate context.


Subject(s)
Epithelial Cells/metabolism , Gene Expression Regulation, Developmental , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cell Surface/genetics , Receptors, Cell Surface/metabolism , Uterus/embryology , Amino Acid Sequence , Animals , Cell Differentiation/genetics , Decidua/embryology , Decidua/metabolism , Female , Mice , Molecular Sequence Data , Organ Specificity , Sequence Homology, Amino Acid , Uterus/cytology , Uterus/metabolism
13.
Oncogene ; 17(26): 3463-9, 1998 Dec 31.
Article in English | MEDLINE | ID: mdl-10030670

ABSTRACT

The Cdk inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, although its expression is induced by a number of mitogens that promote cell proliferation. We have found that E2F1 and E2F3, transcription factors that activate genes required for cell cycle progression, are strong activators of the p21 promoter. In contrast, HBP1 (HMG-box protein-1), a novel retinoblastoma protein-binding protein, can repress the p21 promoter and inhibit induction of p21 expression by E2F. Both E2Fs and HBP1 regulate p21 transcription through cis-acting elements located between nucleotides -119 to +16 of the p21 promoter and the DNA binding domains of each of these proteins are required for activity. Sequences between -119 and -60 basepairs containing four Sp1 consensus elements and two noncanonical E2F binding sites are of major importance for E2F activation, although E2F1 and E2F3 differ in the extent of their ability to activate expression when this segment is deleted. The opposing effects of E2Fs and HBP1 on p21 promoter activity suggest that interplay between these factors may determine the level of p21 transcription in vivo.


Subject(s)
Carrier Proteins , Cyclins/genetics , Cyclins/metabolism , DNA-Binding Proteins , Repressor Proteins/metabolism , Retinoblastoma Protein/metabolism , Transcription, Genetic , Base Sequence , Binding Sites , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cyclin-Dependent Kinase Inhibitor p21 , E2F Transcription Factors , E2F1 Transcription Factor , E2F2 Transcription Factor , E2F3 Transcription Factor , Gene Expression Regulation , Helix-Loop-Helix Motifs/genetics , High Mobility Group Proteins/genetics , High Mobility Group Proteins/metabolism , Humans , Molecular Sequence Data , Promoter Regions, Genetic , Regulatory Sequences, Nucleic Acid , Repressor Proteins/genetics , Retinoblastoma-Binding Protein 1 , Sp1 Transcription Factor/metabolism , Transcription Factor DP1 , Transcription Factors/genetics , Transcription Factors/metabolism , Tumor Cells, Cultured
15.
Cell Growth Differ ; 8(9): 951-61, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9300178

ABSTRACT

The cyclin-dependent kinase, proliferating cell nuclear antigen, and stress-activated protein kinase/c-jun NH2 terminal kinase inhibitor p21WAF1/CIP1 can induce G1 arrest, and its expression coincides with the cessation of replication in many systems. We examined expression of p21 during the early stages of carbon tetrachloride intoxication in the mouse liver and observed a dramatic increase in p21 RNA levels between 4 and 8 h after administration. p21 expression, visualized by in situ hybridization, is induced in pericentral hepatocytes before carbon tetrachloride-induced necrosis. Examination of c-fos and c-myc expression patterns confirm that these immediate-early genes are induced in similar regions of the mouse liver. p21 induction is not dependent on p53; we observed similar levels and localization of p21 in wild-type and p53 null animals. Immunohistochemical localization of p21 and CCAAT/enhancer-binding protein expression shows that p21 protein accumulation is limited to a subset of CCAAT/enhancer-binding protein-positive hepatocytes. A second peak of periportal and intermediate zone-specific p21 gene expression, appearing 1-2 days after injection, is also p53 independent and may represent cell cycle checkpoints or postmitotic growth arrest. Sporadic p21 expression was also detected in pairs of hepatocytes distributed throughout the liver acini in healthy animals. Together, these data suggest several roles for p21 in the liver in response to toxicity, regeneration, and growth inhibition.


Subject(s)
Carbon Tetrachloride/toxicity , Cyclins/biosynthesis , Cyclins/drug effects , Liver/drug effects , Liver/metabolism , Tumor Suppressor Protein p53/physiology , Animals , Cyclin-Dependent Kinase Inhibitor p21 , Gene Expression Regulation/drug effects , Liver/cytology , Male , Mice , Mice, Inbred C3H , Mice, Knockout
16.
Proc Natl Acad Sci U S A ; 94(26): 14477-82, 1997 Dec 23.
Article in English | MEDLINE | ID: mdl-9405638

ABSTRACT

Sik, the mouse homologue of the breast tumor kinase Brk, is expressed in differentiating cells of the gastrointestinal tract and skin. We examined expression and activity of Sik in primary mouse keratinocytes and a mouse embryonic keratinocyte cell line (EMK). Calcium-induced differentiation of these cells has been shown to be accompanied by the activation of tyrosine kinases and rapid phosphorylation of a 65-kDa GTPase-activating protein (GAP)-associated protein (GAP-A.p65). We demonstrate that Sik is activated within 2 min after calcium addition in primary keratinocytes and EMK cells. In EMK cells, Sik binds GAP-A.p65, and this interaction is mediated by the Sik Src homology 2 domain. Although Sik directly complexes with GAP-A.p65, overexpression of wild-type or kinase defective Sik in EMK cells does not lead to detectable changes in GAP-A.p65 phosphorylation. These data suggest that Sik is not responsible for phosphorylation of GAP-A.p65. GAP-A. p65 may act as an adapter protein, bringing Sik into proximity of an unidentified substrate. Overexpression of Sik in EMK cells results in increased expression of filaggrin during differentiation, supporting a role for Sik in differentiation.


Subject(s)
Calcium/metabolism , Keratinocytes/cytology , Keratinocytes/metabolism , Phosphoproteins/metabolism , src-Family Kinases/metabolism , Animals , Cell Differentiation , Cell Line , Mice , Nuclear Proteins/metabolism , Protein-Tyrosine Kinases , Signal Transduction
17.
Proc Soc Exp Biol Med ; 213(2): 138-49, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8931660

ABSTRACT

Progression through the cell cycle is regulated by cyclins and cyclin-dependent kinases (Cdks). The cyclin kinase inhibitor p21 (also known as WAF1, CIP1, SDI1, and MDA-6) can induce G1 arrest and block entry into S phase by inactivating Cdks or by inhibiting activity of proliferating cell nuclear antigen (PCNA). In normal cells, p21 exists in quaternary complexes with cyclin, Cdk, and PCNA. Transcription of the p21 gene is activated by p53-dependent and -independent mechanisms. Mice deficient in p21 exhibit no apparent phenotype, although p21 function has been demonstrated to be necessary for p53-mediated G1 arrest following irradiation of p21-deficient mouse embryonic fibroblasts. Thus, the function of p21 under normal circumstances appears to be redundant. p21 is expressed in terminally differentiating cells of a variety of tissues in a p53-independent manner. Overexpression of p21 results in G1 arrest and has been shown to suppress effectively tumor growth in vitro and in vivo. We review the recent literature describing the functional characterization of p21. This protein plays a key role in regulating the cell cycle and may have potential gene therapy applications.


Subject(s)
Cell Cycle/physiology , Cyclins/physiology , Enzyme Inhibitors , Animals , Cell Cycle/drug effects , Cell Differentiation , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/antagonists & inhibitors , Cyclins/pharmacology , DNA Damage , Humans , Neoplasms/genetics , Neoplasms/pathology
18.
Exp Cell Res ; 227(2): 171-81, 1996 Sep 15.
Article in English | MEDLINE | ID: mdl-8831553

ABSTRACT

We examined the relationship between expression of the p21 (WAF1/CIP1) inhibitor of cyclin-dependent kinases, cessation of proliferation, and terminal differentiation in the epithelia of the gastrointestinal tract. Using in situ hybridization, we performed a detailed study of patterns of p21 mRNA expression in different regions of the stomach, along the length of the intestine, and in tongue, cervix, and hair follicle. We detected strong hybridization only in cells that had ceased proliferation and begun the process of terminal differentiation. Induction of p21 transcription may serve as a useful marker for dissection of differentiation programs in these diverse epithelia. To determine the relative levels of p21 expressed in various regions of the gastrointestinal tract from the esophagus to the colon, we used quantitative RT-PCR with endogenous and exogenous sequences as internal standards. The highest levels of p21 expression were detected in the distal small intestine. To further investigate the role that cell cycle regulation may play during differentiation of intestinal epithelial cells, we examined the expression of p53, p21, cyclin D1, cyclin E, and E2F1 in the Caco-2 colon carcinoma cell line, which differentiates spontaneously after reaching confluence. p21 and p53 mRNA and protein levels increase as Caco-2 cells differentiate. In both undifferentiated and differentiated Caco-2 cells, p53 protein was not inducible by DNA damaging agents, suggesting the absence of functionally wildtype protein. Caco-2 cells should provide a useful model system for studying regulation of p21 and determining if it plays a role during intestinal epithelial cell differentiation.


Subject(s)
Caco-2 Cells/physiology , Cyclins/genetics , Enzyme Inhibitors/metabolism , Interphase/physiology , Blotting, Western , Caco-2 Cells/cytology , Cell Cycle/genetics , Cell Differentiation/genetics , Cell Differentiation/physiology , Cell Division/physiology , Cervix Uteri/cytology , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/metabolism , Epithelial Cells , Epithelium/physiology , Female , Gene Expression Regulation/physiology , Hair Follicle/cytology , Humans , In Situ Hybridization , Intestine, Small/chemistry , Intestine, Small/cytology , RNA, Messenger/analysis , Tongue/cytology
19.
Dev Biol ; 168(2): 395-405, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7537233

ABSTRACT

The alpha-fetoprotein (AFP) gene is transcribed in most epithelial cells lining the fetal mouse small intestine, but transcription persists in only a subset of enteroendocrine cells representing less than 1% of the total intestinal epithelial cells in the adult. The decrease in AFP expression after birth is mediated in part by a repressor element lying between -838 and -250 bp of the AFP gene. Deletion of this element from AFP minigene constructs results in high-level minigene expression in the intestines of adult transgenic mice. Although high levels of AFP minigene RNA are expressed, the fetal pattern of expression is not maintained upon deletion of the repressor element. Instead, the number of cells in which the minigene is expressed increases from less than 1% to approximately 10% of the epithelial cells in the adult small intestine, and includes the majority of the goblet cells in addition to the enteroendocrine cells. In contrast, the pattern of AFP minigene expression in the enterocytes is unaffected by deletion of the repressor element and continues to decrease in the neonate. These studies indicate that the identified AFP repressor is active specifically in goblet cells. The decrease in AFP expression in the enterocytes may be mediated by a separate cis-acting element that is contained in the AFP minigene construct. Alternatively, it is possible that mature enterocytes lack some of the positive factors required for initiation and maintenance of minigene transcription in the absence of the identified negative element.


Subject(s)
Intestine, Small/metabolism , Mice, Transgenic/embryology , alpha-Fetoproteins/biosynthesis , Animals , Embryonic and Fetal Development , Epithelium/metabolism , Gene Expression Regulation, Developmental , Mice , RNA/analysis , alpha-Fetoproteins/genetics
20.
Oncogene ; 10(2): 349-57, 1995 Jan 19.
Article in English | MEDLINE | ID: mdl-7838533

ABSTRACT

A portion of the catalytic domain of a novel tyrosine kinase was cloned from mouse intestinal crypt cells, in a screen designed to identify kinases that may play a role in the regeneration of the intestinal epithelium (E Siyanova, MS Serfas, IA Mazo and AL Tyner, Oncogene 9, 2053-2057). We have cloned a cDNA encoding this kinase, termed sik for src-related intestinal kinase. The sik cDNA encodes a 451 amino acid protein that shares 80% identity with the recently cloned human tyrosine kinase, brk. Sequences found in src family kinases, such as SH2 and SH3 domains and a putative regulatory tyrosine at the carboxy terminus are found in the sik kinase. In contrast, sik lacks a myristylation site. The protein encoded by the sik cDNA has tyrosine kinase activity when expressed in E. coli. We have determined that sik is expressed only in epithelial tissues, including the skin and lining of the alimentary canal, and using in situ hybridization we show that expression of sik mRNA is restricted to the cell layers immediately above the proliferative cell zone in these epithelia. The sik mRNA is first detected at day 15.5 of gestation in the mouse embryo, where it is expressed in the newly forming granular layer of the skin. The restricted expression of sik to differentiating cells of rapidly renewing epithelia suggests that sik may play a specialized role in these tissues.


Subject(s)
Intestines/enzymology , Protein-Tyrosine Kinases/metabolism , Skin/enzymology , src-Family Kinases , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , DNA, Complementary , Epithelium/enzymology , In Situ Hybridization , Mice , Molecular Sequence Data , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...